Manchester Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Manchester Capital Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61K	Hold	300	–	–	0.01%	472
2026 Q1	$56.4K	Hold	300	–	–	0.01%	465
2025 Q4	$56.8K	Hold	300	–	–	0.01%	470
2025 Q3	$49.7K	Hold	300	–	–	0.01%	569
2025 Q2	$46K	Hold	300	–	–	0.01%	580
2025 Q1	$47.2K	Hold	300	–	–	0.01%	560
2024 Q4	$47.1K	Hold	300	–	–	0.01%	548
2024 Q3	$53.2K	Hold	300	–	–	0.01%	528
2024 Q2	$50.5K	Buy	+300	New	+$49.1K	0.01%	503
2014 Q4	–	Sell	-1,780	Closed	-$188K	–	1108
2014 Q3	$188K	Hold	1,780	–	–	0.03%	360
2014 Q2	$170K	Hold	1,780	–	–	0.02%	408
2014 Q1	$162K	Hold	1,780	–	–	0.03%	386
2013 Q4	$158K	Buy	+1,780	New	+$149K	0.02%	384

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Manchester Capital Management's BBH Position: Q2 2026 in Review

Manchester Capital Management held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 300 shares worth $61K. The position accounts for 0.01% of the portfolio, ranked #472.

Manchester Capital Management first reported a position in BBH in Q4 2013 and has held it in 13 quarters since. The position peaked at $188K in Q3 2014. 111 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Manchester Capital Management held 300 shares of VanEck Biotech ETF worth $61K as of Q2 2026.
Manchester Capital Management left its VanEck Biotech ETF share count unchanged in Q2 2026.
VanEck Biotech ETF made up 0.01% of Manchester Capital Management's portfolio in Q2 2026, its #472 holding.
Manchester Capital Management first reported a position in VanEck Biotech ETF in Q4 2013 and has held it in 13 quarters since.
Manchester Capital Management's VanEck Biotech ETF position peaked at $188K in Q3 2014.
111 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.